Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Gains from Investment Securities (2016 - 2025)

Abeona Therapeutics (ABEO) has 14 years of Gains from Investment Securities data on record, last reported at $176019.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities rose 9348.15% year-over-year to $176019.0; the TTM value through Sep 2025 reached $176019.0, up 9348.15%, while the annual FY2024 figure was $176587.0, 1.35% down from the prior year.
  • Gains from Investment Securities reached $176019.0 in Q3 2025 per ABEO's latest filing, up from $408.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $11.7 million in Q4 2023 and bottomed at -$7.5 million in Q2 2024.
  • Average Gains from Investment Securities over 5 years is $782493.2, with a median of $21500.0 recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 279600.0% in 2022, down 157350.0% in 2022.
  • A 5-year view of Gains from Investment Securities shows it stood at -$16000.0 in 2021, then soared by 243.75% to $23000.0 in 2022, then surged by 50717.39% to $11.7 million in 2023, then plummeted by 98.49% to $176587.0 in 2024, then dropped by 0.32% to $176019.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $176019.0 in Q3 2025, $408.0 in Q1 2025, and $176587.0 in Q4 2024.